Hookipa Pharma Inc Expected To Post A Loss Of $1.28 A Share: Earnings Preview

Hookipa Pharma

06/11/2024 14:13

* HOOKIPA Pharma Inc  HOOK.OQ   HOOK.O  is expected to show
a fall
in quarterly revenue when it reports  results on November 7
(estimated) for the period ending September 30 2024
    * The New York City-based  company is expected to report a
9.0% decrease in revenue to $6.25 million from $6.87 million a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for HOOKIPA Pharma Inc is
for a
loss of $1.28 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for HOOKIPA
Pharma
Inc is $50.00​, above​ its last closing price of $3.81. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -1.29       -1.25      -1.52     Missed  -21.4
 Mar. 31 2024  -1.07       -1.02      1.10      Beat    207.3
 Jan. 1 0001   -1.96       -1.93      -2.20     Missed  -14​
 Sep. 30 2023  -2.31       -2.10      -1.70     Beat    19
 ​​Jun.        -1.86       -2.09      -2.20     Missed  -5.3
 30 2023                                                
 Mar. 31 2023  -2.23       -2.26      -2.70     Missed  -19.5​
 Dec. 31 2022  -1.78       -2.15      -1.70     Beat    20.9
 Jan. 1 0001   -2.87       -2.82      -2.50     Beat    11.2
 This summary was machine generated November 6 at 14:12 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)